Email: cspc@cspc.cn

Contact Us
EN

News

News

Home > Media > News > VOLUNTARY ANNOUNCEMENT - HIGHLY SELECTIVE PDE4B INHIBITOR (SYH2059 POWDER FOR INHALATION) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.

VOLUNTARY ANNOUNCEMENT - HIGHLY SELECTIVE PDE4B INHIBITOR (SYH2059 POWDER FOR INHALATION) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.

March 16, 2026

a260306_00.png

Previous: VOLUNTARY ANNOUNCEMENT - GLP-1/GIP RECEPTOR DUAL-BIASED AGONIST POLYPEPTIDE LONG-ACTING INJECTION (SYH2082 INJECTION) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA

Next: VOLUNTARY ANNOUNCEMENT - INDACATEROL ACETATE AND MOMETASONE FUROATE POWDER FOR INHALATION OBTAINS CLINICAL TRIAL APPROVAL IN CHINA

Contact Us

Phone:

+86 311 8703 7015

Email:

cspc@cspc.cn

Products

Science

About Us

Legal terms Privacy protection
Copyright © CSPC PHARMACEUTICAL GROUP LIMITED All Rights Reserved | 冀ICP备05003393号

Wechat